SCHEMBL995481

SCHEMBL995481

c1ccc2[nH]c(-c3ncc4sccc4n3)cc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
CYP19A1 P11511 1/20 0.41
GSK3B P49841 1/20 0.40
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
ITK Q08881 2/20 0.38
ESR1 P03372 3/20 0.38
KDM4E B2RXH2 4/20 0.38
MAPT P10636 4/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
KMT2A Q03164 3/20 0.38
CASP3 P42574 2/20 0.38
SENP8 Q96LD8 2/20 0.38
SENP7 Q9BQF6 2/20 0.38
SENP6 Q9GZR1 2/20 0.38
CHEK1 O14757 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043730 0.79 RAB9A (0.49) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL4825949 0.72 NPC1 (0.49) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL4753026 0.72 GSK3B (0.43) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL30337474 0.70 ITK (0.57) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL2489128 0.70 ITK (0.57) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL1799025 0.70 METAP1 (0.50) RAB9ANPC1CYP19A1GSK3BATP4A
SCHEMBL28399450 0.69 RAB9A (0.61) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL20362359 0.69 NPC1 (0.56) RAB9ANPC1CYP19A1ATP4AATP4B
SCHEMBL2396572 0.69 CDK2 (0.44) RAB9ANPC1CYP19A1GSK3BITK
SCHEMBL18871162 0.68 NPC1 (0.54) RAB9ANPC1CYP19A1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205610-B1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS HOFFMANN LA ROCHE (CH) 2013-11-20 EP disclosed
US-8293735-B2 Thienopyrimidine derivatives as P13K inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2012-10-23 US disclosed
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-27 US disclosed
EP-2205610-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009053715-A1 THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021496-A1 THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS PIK3CA, PIK3CD, PIK3CB RAB9A 2206/4885NPC1 4124/4885CYP19A1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.